| Name | Lenvatinib mesylate |
| Description | Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities. |
| In vitro | Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).?These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.82 mM), Sonication is recommended. DMSO : 32.67 mg/mL (62.47 mM), Sonication is recommended.
|
| Keywords | VEGFR3 | VEGFR1 | VEGFR | Vascular endothelial growth factor receptor | SCFR | RET | Platelet-derived growth factor receptor | PDGFRβ | PDGFRα | PDGFR | Lenvatinib mesylate | Lenvatinib | Inhibitor | inhibit | Fibroblast growth factor receptor | FGFR1 | FGFR | E-7080 | E7080 | E 7080 | cRET | c-Kit | cKit | CD117 |
| Inhibitors Related | Ribociclib | Gilteritinib | Amlexanox | Sorafenib | Ferulic Acid | Dasatinib | Pexidartinib | Nintedanib esylate | Chloramphenicol | Formononetin | Lenvatinib | Pazopanib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Cancer Active Compound Library |